S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 23.9 HKD Market Closed
Market Cap: 13B HKD
Have any thoughts about
Shanghai Henlius Biotech Inc?
Write Note
Shanghai Henlius Biotech Inc
/
Balance Sheet
/
Accumulated Depreciation

Shanghai Henlius Biotech Inc
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai Henlius Biotech Inc
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai Henlius Biotech Inc
HKEX:2696
Accumulated Depreciation
-¥601.8m
CAGR 3-Years
-38%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accumulated Depreciation
-¥2B
CAGR 3-Years
-59%
CAGR 5-Years
-94%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accumulated Depreciation
-¥787.8m
CAGR 3-Years
-30%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accumulated Depreciation
-¥1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Accumulated Depreciation
-¥159.8m
CAGR 3-Years
-70%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
No Stocks Found

Shanghai Henlius Biotech Inc
Glance View

Market Cap
13B HKD
Industry
Biotechnology

In the heart of China's bustling financial district, Shanghai Henlius Biotech Inc. stands proud as a beacon of innovation in the biopharmaceutical industry. Founded in 2010, Henlius has rapidly grown to become a notable player in the development of monoclonal antibodies, with a focus on oncology, autoimmune disorders, and ophthalmic conditions. The company's business model is rooted in its robust research and development capabilities, which are supported by strategic partnerships and a dedicated pipeline. By harnessing state-of-the-art technology and a global talent pool, Henlius crafts biosimilar and innovative biological drugs designed to meet the escalating health needs across the globe. With a strong focus on cutting-edge R&D, they have successfully commercialized several key products that have gained regulatory approval, allowing them to penetrate both domestic and international markets. Revenue flows into Henlius through a diversified portfolio that stretches beyond drug development to encompass manufacturing and sales partnerships. By leveraging their fully-integrated biopharmaceutical platform, Henlius not only develops its proprietary medications but also collaborates with other pharmaceutical giants to bring products to market efficiently. These collaborations often translate into licensing agreements and royalties, which provide Henlius with recurring income streams. The company's ability to navigate complex regulatory environments and its strategic expansion into global markets – including Europe, Southeast Asia, and Latin America – further reinforces its revenue-generating capacity. Thus, Henlius stands as a testament to the power of strategic ingenuity and cutting-edge science in the ever-evolving landscape of global healthcare.

Intrinsic Value
25.21 HKD
Undervaluation 5%
Intrinsic Value
Price
S
What is Intrinsic Value?

See Also

What is Shanghai Henlius Biotech Inc's Accumulated Depreciation?
Accumulated Depreciation
-601.8m CNY

Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Accumulated Depreciation amounts to -601.8m CNY.

What is Shanghai Henlius Biotech Inc's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-44%

Over the last year, the Accumulated Depreciation growth was -33%. The average annual Accumulated Depreciation growth rates for Shanghai Henlius Biotech Inc have been -38% over the past three years , -44% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.